Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation.

Trial Profile

Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs 64Cu-MeCOSar-Octreotate (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Clarity Pharmaceuticals
  • Most Recent Events

    • 08 Dec 2017 According to a Clarity Pharmaceuticals media release, Additional sites in Australia and the USA will be activated over the coming months in order to fast-track the completion of this trial.
    • 08 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Clarity Pharmaceuticals media release.
    • 08 Nov 2017 According to a Clarity Pharmaceuticals media release, site activation at the Childrens Hospital at Westmead in Sydney has been completed and recruitment has commenced has been commenced.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top